AstraZeneca ROA 2010-2024 | AZN

Current and historical return on assets (ROA) values for AstraZeneca (AZN) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
AstraZeneca ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2024-03-31 $6.33B $102.29B 6.39%
2023-12-31 $5.96B $101.12B 6.10%
2023-09-30 $5.90B $96.09B 6.12%
2023-06-30 $6.16B $96.54B 6.42%
2023-03-31 $4.71B $96.69B 4.90%
2022-12-31 $3.29B $96.48B 3.39%
2022-09-30 $2.04B $94.19B 2.06%
2022-06-30 $-1.25B $96.58B -1.22%
2022-03-31 $-1.06B $100.27B -1.10%
2021-12-31 $0.11B $105.36B 0.13%
2021-09-30 $1.47B $107.22B 1.88%
2021-06-30 $3.77B $73.64B 5.60%
2021-03-31 $3.98B $64.93B 6.22%
2020-12-31 $3.20B $66.73B 5.16%
2020-09-30 $2.50B $64.11B 4.12%
2020-06-30 $2.15B $59.93B 3.62%
2020-03-31 $1.52B $57.21B 2.54%
2019-12-31 $1.34B $61.38B 2.20%
2019-09-30 $2.06B $58.91B 3.39%
2019-06-30 $2.19B $61.89B 3.57%
2019-03-31 $2.41B $61.06B 3.94%
2018-12-31 $2.16B $60.65B 3.49%
2018-09-30 $2.42B $61.44B 3.88%
2018-06-30 $2.68B $61.34B 4.24%
2018-03-31 $2.80B $63.28B 4.38%
2017-12-31 $3.00B $63.35B 4.73%
2017-09-30 $3.54B $64.59B 5.60%
2017-06-30 $3.87B $65.12B 6.15%
2017-03-31 $3.39B $60.96B 5.40%
2016-12-31 $3.50B $62.53B 5.50%
2016-09-30 $2.47B $63.22B 3.91%
2016-06-30 $2.22B $64.42B 3.66%
2016-03-31 $2.92B $64.32B 5.00%
2015-12-31 $2.83B $60.06B 5.07%
2015-09-30 $1.70B $54.12B 3.06%
2015-06-30 $1.18B $55.17B 2.11%
2015-03-31 $1.28B $53.70B 2.25%
2014-12-31 $1.23B $58.60B 2.12%
2014-09-30 $1.03B $56.16B 1.79%
2014-06-30 $2.02B $58.54B 3.55%
2014-03-31 $2.05B $59.39B 3.67%
2013-12-31 $2.56B $55.90B 4.73%
2013-09-30 $4.59B $54.12B 8.57%
2013-06-30 $4.85B $53.99B 9.14%
2013-03-31 $5.63B $52.33B 10.73%
2012-12-31 $6.24B $53.53B 11.99%
2012-09-30 $6.23B $52.45B 12.01%
2012-06-30 $8.19B $51.39B 15.79%
2012-03-31 $8.71B $50.76B 16.62%
2011-12-31 $9.99B $52.83B 18.73%
2011-09-30 $10.13B $52.58B 18.70%
2011-06-30 $8.21B $53.41B 14.89%
2011-03-31 $8.21B $54.53B 14.81%
2010-12-31 $8.08B $56.13B 14.61%
2010-09-30 $8.01B $56.39B 14.56%
2010-06-30 $8.57B $54.65B 15.90%
2010-03-31 $8.16B $54.08B 15.46%
2009-12-31 $7.53B $54.92B 14.79%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $245.469B $45.811B
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $834.732B 120.64
Novo Nordisk (NVO) Denmark $598.098B 45.96
Johnson & Johnson (JNJ) United States $366.658B 14.54
Merck (MRK) United States $315.030B 57.32
AbbVie (ABBV) United States $305.760B 15.80
Novartis AG (NVS) Switzerland $220.139B 15.30
Pfizer (PFE) United States $167.164B 20.77
Sanofi (SNY) $127.725B 12.04
Innoviva (INVA) United States $1.113B 7.82